View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 9, 2022

Moderna’s booster vaccine shows antibody response against Omicron

A booster shot of mRNA-1273.214 was found to be well-tolerated with side effects in line with a booster dose of mRNA-1273.

Moderna has reported new findings from Phase II/III clinical trial where its Omicron-containing bivalent Covid-19 booster candidate, mRNA-1273.214, showed greater antibody response against the Omicron variant of the SARS-CoV-2 virus.

The mRNA-1273.214 vaccine comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the Omicron variant. 

According to the latest data, a 50µg booster dose of the vaccine met all pre-specified endpoints including greater neutralising antibody response (geometric mean ratio (GMR)) against Omicron one month following dosing versus the mRNA-1273 vaccine. 

Furthermore, the booster shot of mRNA-1273.214 was found to be well-tolerated with side effects in line with the booster dose of mRNA-1273.

The GMR and corresponding 97.5% confidence interval were reported to be 1.75. 

A booster dose of mRNA-1273.214 raised neutralising geometric mean titers (GMT) against Omicron nearly eight-fold above baseline levels. 

In addition, the trial met primary endpoints of non-inferiority against ancestral SARS-CoV-2, with GMR against this virus being 1.22.

A month after dosing, the neutralising GMT against ancestral SARS-CoV-2 for mRNA-1273.214 was 5977 versus 5649 for mRNA-1273 in seronegative subjects. 

The GMT against Omicron for mRNA-1273.214 was 2372 versus 1473 for mRNA-1273.

As against mRNA-1273, binding antibody titers (MSD) were found to be substantially raised against all other variants of concern for mRNA-1273.214. 

A 50μg booster dose of mRNA-1273.214 had safety and reactogenicity profile in line with 50μg mRNA-1273 when these vaccines were given as a second booster shot.

Moderna CEO Stéphane Bancel said: “We are thrilled to share the preliminary data analysis on mRNA-1273.214, which is the second demonstration of superiority of our bivalent booster platform against variants of concern and represents an innovation in the fight against Covid. 

“Looking at these data alongside the durability we saw with our first bivalent booster candidate, mRNA-1273.211, we anticipate more durable protection against variants of concern with mRNA-1273.214, making it our lead candidate for a fall 2022 booster.” 

The company anticipates submitting the interim assessment and findings to regulatory agencies for review soon.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena